Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice

PURPOSE: Prostate-specific antigen (PSA) response rate (>50% PSA decline in pretreatment PSA following chemotherapy) carries a significant survival advantage in castration-resistant prostate cancer (CRPC). We compared PSA response rates in first-, second- and third-line chemotherapy after failure...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Geehyun, Lee, Chunwoo, You, Dalsan, Jeong, In Gab, Hong, Jun Hyuk, Ahn, Hanjong, Kim, Choung-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society (APPS) 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3814118/
https://www.ncbi.nlm.nih.gov/pubmed/24223414
http://dx.doi.org/10.12954/PI.13024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3814118/
https://www.ncbi.nlm.nih.gov/pubmed/24223414
http://dx.doi.org/10.12954/PI.13024

Ejemplares similares